What the FDA labels say about taking them together
Glecaprevir/pibrentasvir and rosuvastatin
Glecaprevir/pibrentasvir's FDA label of June 25, 2025 names rosuvastatin in its drug interactions section, and rosuvastatin's label names glecaprevir/pibrentasvir too. The glecaprevir/pibrentasvir label: “Coadministration may significantly increase the concentration of rosuvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. …”
Check it at the source: the glecaprevir/pibrentasvir FDA label on DailyMed (effective June 25, 2025, AbbVie Inc.); the rosuvastatin FDA label on DailyMed (effective September 4, 2026, ScieGen Pharmaceuticals, Inc.).
What does the glecaprevir/pibrentasvir label say about rosuvastatin?
Glecaprevir/pibrentasvir label, drug interactionsConcomitant Drug Class/Drug Name: Rosuvastatin; Effect on Concentration: ↑ rosuvastatin; Clinical Comments: Coadministration may significantly increase the concentration of rosuvastatin. Increased statin concentrations may increase the risk of myopathy, including rhabdomyolysis. Rosuvastatin may be administered with MAVYRET at a dose that does not exceed 10 mg.
Source: FDA drug label (Mavyret), AbbVie Inc., effective June 25, 2025 (SPL set 7bf99777-0401-9095-8645-16c6e907fcc0), via openFDA; the full label on DailyMed
What does the rosuvastatin label say about glecaprevir/pibrentasvir?
Rosuvastatin label, drug interactionsAdditional Anti-Viral Medications Prevention or Management: Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin 5 mg once daily, and do not exceed a dosage of rosuvastatin 10 mg once daily.
Crestor label (AstraZeneca Pharmaceuticals LP, April 29, 2026), drug interactionsGlecaprevir/pibrentasvir
Source: FDA drug label (Crestor, NDA021366), AstraZeneca Pharmaceuticals LP, effective April 29, 2026 (SPL set 325a5d0e-9a72-4015-9fcd-1655fb504cee), via openFDA
Source: FDA drug label (Rosuvastatin), ScieGen Pharmaceuticals, Inc., effective September 4, 2026 (SPL set ee4933c5-0d97-494d-ac0f-2083e0100836), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Glecaprevir/pibrentasvir | Rosuvastatin | |
|---|---|---|
| Labeled for | Hepatitis C | Heart attack and coronary artery disease, High cholesterol, High triglycerides, Stroke prevention |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | $152.98 per tablet 100-40 mg tablet | $0.0692 per tablet 40 mg tablet |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once